Literature DB >> 28459968

Human Leukocyte Antigen Shared Epitope and Inflammation, Cardiovascular Disease, Cancer, and Mortality Among Postmenopausal Women in the Women's Health Initiative Rheumatoid Arthritis Study.

Mehret Birru Talabi, Rachel H Mackey, Lewis H Kuller, Janice S Dorman, Kevin D Deane, William H Robinson, Brian T Walitt, Yuefang Chang, V Michael Holers, Simin Liu, Larry W Moreland.   

Abstract

Specific alleles of the human leukocyte antigen (HLA)-DRB1 gene (HLA-DRB1) encode a "shared epitope" (SE) associated with rheumatoid arthritis (RA), especially more severe cyclic-citrullinated peptide antibody-positive (anti-CCP+) RA. We evaluated associations of number of SE alleles (0, 1, or 2) with total and cardiovascular disease (CVD) mortality and incident coronary heart disease (CHD), CVD, and cancer over a mean 8.9 (standard deviation, 3.5) years of follow-up, stratifying by baseline anti-CCP status (positive (+) vs. negative (-)). A longitudinal study, the Women's Health Initiative RA Study (1993-2010), sampled postmenopausal women who reported RA at baseline (1993-1998) or follow-up in the Women's Health Initiative, classified as anti-CCP+ RA (n = 556) or anti-CCP- non-RA (n = 1,070). Among anti-CCP+ RA women, SE alleles were not related to age-adjusted risks of CHD, CVD, or cancer or to total or CVD mortality. Among anti-CCP- non-RA women, age-adjusted hazard ratios for 1 and 2 SE alleles versus 0 SE alleles were 0.41 (95% confidence interval (CI): 0.34, 0.50) and 0.44 (95% CI: 0.27, 0.72), respectively, for CVD; 0.43 (95% CI: 0.37, 0.53) and 0.30 (95% CI: 0.16, 0.64), respectively, for CHD; and 0.62 (95% CI: 0.53, 0.73) and 0.52 (95% CI: 0.33, 0.83), respectively, for cancer. Associations persisted after adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammatory markers (white blood cell count or cytokine level). In future studies, investigators should evaluate SE associations among anti-CCP- adults without RA and potential mechanisms.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HLA-DRB1 gene; cancer; cardiovascular disease; human leukocyte antigen; mortality; rheumatoid arthritis; shared epitope

Mesh:

Substances:

Year:  2017        PMID: 28459968      PMCID: PMC5860272          DOI: 10.1093/aje/kwx087

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  44 in total

1.  Outcomes ascertainment and adjudication methods in the Women's Health Initiative.

Authors:  J David Curb; Anne McTiernan; Susan R Heckbert; Charles Kooperberg; Janet Stanford; Michael Nevitt; Karen C Johnson; Lori Proulx-Burns; Lisa Pastore; Michael Criqui; Sandra Daugherty
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

2.  Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles.

Authors:  S P Linn-Rasker; A H M van der Helm-van Mil; F A van Gaalen; M Kloppenburg; R R P de Vries; S le Cessie; F C Breedveld; R E M Toes; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 3.  MHC class I antigens and immune surveillance in transformed cells.

Authors:  Natalia Aptsiauri; Teresa Cabrera; Angel Garcia-Lora; Miguel Angel Lopez-Nevot; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Int Rev Cytol       Date:  2007

4.  Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study.

Authors:  Karen L Margolis; JoAnn E Manson; Philip Greenland; Rebecca J Rodabough; Paul F Bray; Monika Safford; Richard H Grimm; Barbara V Howard; Annlouise R Assaf; Ross Prentice
Journal:  Arch Intern Med       Date:  2005-03-14

5.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

6.  Association of anti-cyclic citrullinated peptide antibodies with clinical and radiological disease severity in rheumatoid arthritis.

Authors:  Ankit Gupta; Reshma Kaushik; Rajeev M Kaushik; Manju Saini; Rajesh Kakkar
Journal:  Curr Rheumatol Rev       Date:  2014

Review 7.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

8.  Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.

Authors:  Floris A van Gaalen; Jill van Aken; Tom W J Huizinga; Geziena M Th Schreuder; Ferdinand C Breedveld; Eric Zanelli; Walther J van Venrooij; Cornelis L Verweij; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2004-07

9.  A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.

Authors:  J van Holten; K Pavelka; J Vencovsky; H Stahl; B Rozman; M Genovese; A J Kivitz; J Alvaro; G Nuki; D E Furst; G Herrero-Beaumont; I B McInnes; P Musikic; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

10.  Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.

Authors:  Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

View more
  2 in total

1.  HLA-DRB1 Haplotypes, Shared Epitope, and Disease Outcomes in US Veterans with Rheumatoid Arthritis.

Authors:  Ming Zhao; Lilli Mauer; Harlan Sayles; Grant W Cannon; Andreas Reimold; Gail S Kerr; Joshua F Baker; Geoffrey M Thiele; Bryant R England; Ted R Mikuls
Journal:  J Rheumatol       Date:  2019-03-01       Impact factor: 4.666

2.  CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma.

Authors:  Zhengyu Wei; Yiming Shen; Chongchang Zhou; Yujie Cao; Hongxia Deng; Zhisen Shen
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.